How we diagnose and treat neutropenia in adults

References

• Wright DG, Palmblad J. Acquired neutropenia and agranulocytosis. In: Young N, Gerson SL, High KA, editors. Clinical hematology. Philadelphia (PA): Moseby Elsevier; 2006. p. 192–202.
   Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• Walkovich K, Boxer LA. How to approach neutropenia in childhood. Pediatr Rev. 2013;34:173–184.
   PubMedGoogle Scholar
• Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenias: consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Am J Hematol. 2012;87:238–243.
   PubMed Web of Science ®Google Scholar
• Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Pediatr Blood Cancer. 2011;57:10–17.
   PubMed Web of Science ®Google Scholar
• Palmblad J, Dufour C, Papadaki HA. How we diagnose neutropenia in the adult and elderly patient. Haematologica. 2014;99:1130–1336.
   PubMed Web of Science ®Google Scholar
• Husain EH, Mullah-Ali A, Al-Sharidah S, et al. Infectious etiologies of transient neutropenia in previously healthy children. Pediatr Infect Dis J. 2012;31:575–577.
   PubMed Web of Science ®Google Scholar
• Shi X, Sims MD, Hanna MM, et al. Neutropenia during HIV infection: adverse consequences and remedies. Int Rev Immunol. 2014;33:511–536.
   PubMed Web of Science ®Google Scholar
• Sheehan VA, Weir A, Waters B. Hepatitis C and neutropenia. Curr Opin Hematol. 2014;21:58–63.
   PubMed Web of Science ®Google Scholar
• Andrès E, Zimmer J, Mecili M, et al. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4:143–151.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84:428–434.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011;4:619–625.
   PubMed Web of Science ®Google Scholar
• Newburger PE, Pindyck TN, Zhu Z, et al. Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype: evidence for phenotype determination by modifying genes. Pediatr Blood Cancer. 2010;55:314–317.
   PubMed Web of Science ®Google Scholar
• Ye Y, Carlsson G, Wondimu B, et al. Mutations in the ELANE gene are associated with development of periodontitis in patients with severe congenital neutropenia. J Clin Immunol. 2011;31:936–945.
   PubMed Web of Science ®Google Scholar
• Karlsson J, Carlsson G, Ericson KG, et al. Expression of the antibacterial peptide LL-37 in patients with different types of chronic neutropenia. Br J Haematol. 2007;137:166–169.
   PubMed Web of Science ®Google Scholar
• Cada M, Segbefia CI, Klaassen R, et al. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. Haematologica. 2015;100:633–642.
   PubMed Web of Science ®Google Scholar
• Makaryan V, Zeidler C, Bolyard AA, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol. 2015;22:3–11.
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010;150:196–199.
   PubMed Web of Science ®Google Scholar
• Available from: http://depts.washington.edu/registry and http://www.severe-chronic-neutropenia.org/
   Google Scholar
• Thobakgale CF, Ndung’u T. Neutrophil counts in persons of African origin. Curr Opin Hematol. 2014;21:50–57.
   PubMed Web of Science ®Google Scholar
• Reich D, Nalls MA, Kao WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet. 2009;5:e1000360.
   PubMed Web of Science ®Google Scholar
• Paz Z, Nails M, Ziv E. The genetics of benign neutropenia. Isr Med Assoc J. 2011;13:625–629.
   PubMed Web of Science ®Google Scholar
• Newman K, Owlia MB, El-Hemaidi I, et al. Management of immune cytopenias in patients with systemic lupus erythematosus – old and new. Autoimmun Rev. 2013;12:784–791.
   PubMed Web of Science ®Google Scholar
• Day RB, Link DC. Regulation of neutrophil trafficking from the bone marrow. Cell Mol Life Sci. 2012;69:1415–1423.
   PubMed Web of Science ®Google Scholar
• Klein C. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. Annu Rev Immunol. 2011;29:399–413.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008;25:374–379.
   PubMed Web of Science ®Google Scholar
• Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011;118:4963–4966.
   PubMed Web of Science ®Google Scholar
• McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123:2308–2316.
   PubMed Web of Science ®Google Scholar
• Van Den Tooren-De Groot R, Ottink M, Huiskes E, et al. Management and outcome of 35 cases with foetal/neonatal alloimmune neutropenia. Acta Paediatr. 2014;103:e467–e474.
   Google Scholar
• Varghese AS, Lee H, Bonney D, et al. Complications of reduced intensity conditioning HSCT for XIAP deficiency (alloimmune cytopenias and HLH) successfully managed with donor lymphocyte infusion. J Pediatr Hematol Oncol. 2015;37:e198–e199.
   Google Scholar
• Lucas G, Porcelijn L, Fung YL, et al. External quality assessment of human neutrophil antigen (HNA)-specific antibody detection and HNA genotyping from 2000 to 2012. Vox Sang. 2013;105:259–269.
   PubMed Web of Science ®Google Scholar
• Muschter S, Berthold T, Greinacher A. Developments in the definition and clinical impact of human neutrophil antigens. Curr Opin Hematol. 2011;18:452–460.
   PubMed Web of Science ®Google Scholar
• Storch EK, Hillyer CD, Shaz BH. Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood. 2014;124:1868–1872.
   PubMed Web of Science ®Google Scholar
• Spanoudakis M, Koutala H, Ximeri M, et al. T-cell receptor Vβ repertoire analysis in patients with chronic idiopathic neutropenia demonstrates the presence of aberrant T-cell expansions. Clin Immunol. 2010;137:384–395.
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011;117:2764–2774.
   PubMed Web of Science ®Google Scholar
• Skokowa J, Steinemann D, Katsman-Kuipers JE, et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood. 2014;123:2229–2237.
   PubMed Web of Science ®Google Scholar
• Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013 Jul;50(3):198–206.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Olson T, Clemente MJ, et al. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica. 2015;100:91–99.
   PubMed Web of Science ®Google Scholar
• Youinou P, Jamin C, Le Pottier L, et al. Diagnostic criteria for autoimmune neutropenia. Autoimmun Rev. 2014;13:574–576.
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Pontikoglou C. Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Expert Rev Hematol. 2008;1(2):217–229.
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Stamatopoulos K, Damianaki A, et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. Br J Haematol. 2005;128:863–876.
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Eliopoulos AG, Kosteas T, et al. Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood. 2003;101:2591–2600.
   PubMed Web of Science ®Google Scholar
• Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26:1730–1741.
   PubMed Web of Science ®Google Scholar
• Fioredda F, Calvillo M, Lanciotti M, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer. 2010;54:465–467.
   PubMed Web of Science ®Google Scholar
• Beaupain B, Leblanc T, Reman O, et al. Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer. 2009;53:1068–1073.
   PubMed Web of Science ®Google Scholar
• Miano M, Scalzone M, Perri K, et al. Mycophenolate mofetil and sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience. Br J Haematol. 2015 Jun 8;171:247–253. doi:10.1111/bjh.13533.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Zickl L, Olson TL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29:886–894.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy AM, El-Alfy MS, Sari TT, et al. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. Eur J Haematol. 2014;92:337–340.
   PubMed Web of Science ®Google Scholar
• Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood. 2014;124:1251–1258.
   PubMed Web of Science ®Google Scholar
• Andersen CL, Tesfa D, Siersma VD, et al. Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts. J Intern Med. 2016 Jan 21. doi:10.1111/joim.12467. [Epub ahead of print]
   PubMedGoogle Scholar